dc.contributor.author | Çakal, Beytullah | |
dc.contributor.author | Çakal, Sinem | |
dc.contributor.author | Boztosun, Bilal | |
dc.date.accessioned | 2020-12-25T10:29:16Z | |
dc.date.available | 2020-12-25T10:29:16Z | |
dc.date.issued | 2020 | en_US |
dc.identifier.citation | Çakal, B., Çakal, S. ve Boztosun, B. (2020). Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds. 32nd Annual Transcatheter Cardiovascular Therapeutics Symposium (TCT CONNECT) içinde (B118-B119. ss.). Electr Network, October 14-18, 2020. | en_US |
dc.identifier.issn | 0735-1097 | |
dc.identifier.issn | 1558-3597 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/6146 | |
dc.description.abstract | BACKGROUND The vast majority of clinical trials regarding bioresorbable vascular scaffold (BVS) use came from comparison of everolimus-eluting scaffolds with metallic stents, and it remains unclearwhether similar results would be true when a different type of BVS isused. This study sought to evaluate the long-term performance ofnovolimus-eluting bioresorbable vascular scaffolds (nBVSs) comparedwith everolimus-eluting bioresorbable vascular scaffolds (eBVS).METHODS A total of 140 patients with nBVS (n ¼ 202 before exclusion) and 98 patients with eBVS (n ¼ 135 before exclusion) wereincluded in current study. After propensity-score matching, 98 patients treated with 135 eBVSs were compared with 98 patients treatedwith 136 nBVSs. The primary outcome was the 3-year rate of majoradverse cardiovascular events, defined as the composite of cardiacdeath, target vessel myocardial infarction, and target lesionrevascularization. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier Science Inc | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Bioresorbable Vascular Scaffolds | en_US |
dc.subject | Everolimus | en_US |
dc.subject | Novolimus | en_US |
dc.title | Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds | en_US |
dc.type | conferenceObject | en_US |
dc.relation.ispartof | 32nd Annual Transcatheter Cardiovascular Therapeutics Symposium (TCT CONNECT) | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0003-0230-6575 | en_US |
dc.authorid | 0000-0003-2714-4584 | en_US |
dc.authorid | 0000-0002-4951-6716 | en_US |
dc.identifier.volume | 76 | en_US |
dc.identifier.issue | 17 | en_US |
dc.identifier.startpage | B118 | en_US |
dc.identifier.endpage | B119 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.identifier.wosquality | Q1 | en_US |